Ideaya Biosciences Inc (NASDAQ:IDYA)’s traded shares stood at 1.11 million during the last session, with the company’s beta value hitting 0.25. At the close of trading, the stock’s price was $20.13, to imply an increase of 2.18% or $0.43 in intraday trading. The IDYA share’s 52-week high remains $44.42, putting it -120.67% down since that peak but still an impressive 33.18% since price per share fell to its 52-week low of $13.45. The company has a valuation of $1.76B, with an average of 1.47 million shares in intraday trading volume over the past 10 days and average of 1.21 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Ideaya Biosciences Inc (IDYA), translating to a mean rating of 1.15. Of 11 analyst(s) looking at the stock, 0 analyst(s) give IDYA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 10 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.69.
Ideaya Biosciences Inc (NASDAQ:IDYA) trade information
After registering a 2.18% upside in the last session, Ideaya Biosciences Inc (IDYA) has traded red over the past five days. The 5-day price performance for the stock is 6.96%, and 22.89% over 30 days. With these gigs, the year-to-date price performance is -21.67%. Short interest in Ideaya Biosciences Inc (NASDAQ:IDYA) saw shorts transact 10.67 million shares and set a 7.06 days time to cover.
The extremes give us $27 and $27 for target low and target high price respectively. As such, IDYA has been trading -34.13% off suggested target high and -34.13% from its likely low.
Ideaya Biosciences Inc (IDYA) estimates and forecasts
The rating firms project that company’s revenue will grow 131.71% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 2.1M. Meanwhile, for the current quarter, a total of 10 analyst(s) estimate revenue growth to 2.4M.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -0.01% for the past 5-year period. While 2025 is set for a 16.94% return in earnings, projections for the next 5 years are at 15.86% annually.
IDYA Dividends
Ideaya Biosciences Inc has its next earnings report out on 2025-Feb-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Ideaya Biosciences Inc (NASDAQ:IDYA)’s Major holders
Ideaya Biosciences Inc insiders hold 1.04% of total outstanding shares, with institutional holders owning 109.58% of the shares at 110.73% float percentage. In total, 109.58% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 11.27 million shares (or 14.4557% of shares), all amounting to roughly $395.69 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 6.81 million shares, or about 8.7321% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $239.02 million.
We also have Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Ideaya Biosciences Inc (IDYA) shares. Going by data provided on Feb 28, 2025 , Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund holds roughly 4.1 shares. This is just over 4.68% of the total shares, with a market valuation of $82.53 million. Data from the same date shows that the other fund manager holds a little less at 2.71, or 3.09% of the shares, all valued at about 54.46 million.
